Emphysema itself is not a contraindication to the New Crown vaccine, and patients can receive the New Crown vaccine if they are in the stable stage of emphysema. If the patient is in the acute exacerbation phase, with symptoms such as cough, shortness of breath, chest tightness, and breathlessness, it is recommended that the New Crown vaccine be withheld until the patient enters the stabilization phase. Patients in acute exacerbation may have a significant decrease in lung function and may also have hypoxemia or respiratory failure and infection. Injecting New Crown vaccine at this time may cause or aggravate adverse reactions in the body, so anti-infective and antiasthmatic medications should be given first, and the New Crown vaccine should be administered after the condition has stabilized. In addition, most of the vaccines inject inactivated virus into the human body to produce antibodies through immune response for preventive purposes. Since the immunity of emphysema patients is reduced and their lung function is lowered, the body may not be able to produce an effective immune response after the injection of the new crown vaccine. Therefore, it is best for emphysema patients to wait until the symptoms of acute exacerbation are relieved and the body’s immunity and lung function have recovered to a certain extent before receiving the New Crown vaccine, at which time the vaccine is relatively more effective. Patients with emphysema are advised to consult their local vaccinators before receiving the New Crown vaccine to assess their physical condition and disease status before deciding whether to receive the New Crown vaccine. It is important to observe any side effects after vaccination, and to detect and give targeted treatment for side effects of the vaccine in a timely manner.